Back to search

Article

A SARS-CoV-2 neutralizing antibody selected from COVID-19 patients by phage display is binding to the ACE2-RBD interface and is tolerant to most known recently emerging RBD mutations

2020-12-03

Abstract excerpt

The novel betacoranavirus SARS-CoV-2 causes a form of severe pneumonia disease, termed COVID-19 (coronavirus disease 2019). Recombinant human antibodies are proven potent neutralizers of viruses and can block the interaction of viral surface proteins with their host receptors. To develop neutralizing anti-SARS-CoV-2 antibodies, antibody gene libraries from convalescent COVID-19 patients were constructed and recomb...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work
ea604eba-7a6e-5043-8ecc-a5604ef25876
DOI
10.1101/2020.12.03.409318
Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest
Interactive article relationship graphSelect a related publication card to move it into the centre and load its closest explainable connections. Solid lines are source-backed structured connections. Dashed lines are semantic discovery signals and are not scientific evidence.
A SARS-CoV-2 neutralizing antibody selected from COVID-19 patients by phage display is binding to the ACE2-RBD interface and is tolerant to most known recently emerging RBD mutationsDOI 10.1101/2020.12.03.409318
A SARS-CoV-2 Neutralizing Antibody Selected from COVID-19 Patients by Phage Display is Binding to the ACE2-RBD Interface and is Tolerant to Known RBD MutationsSemantic proximity
A SARS-CoV-2 neutralizing antibody selected from COVID-19 patients binds to the ACE2-RBD interface and is tolerant to most known RBD mutations.Semantic proximity
SARS-CoV-2 neutralizing human recombinant antibodies selected from pre-pandemic healthy donors binding at RBD-ACE2 interfaceSemantic proximity
SARS-CoV-2 neutralizing human recombinant antibodies selected from pre-pandemic healthy donors binding at RBD-ACE2 interface.Semantic proximity
Cross-neutralization antibodies against SARS-CoV-2 and RBD mutations from convalescent patient antibody librariesSemantic proximity
A human monoclonal antibody targeting a conserved pocket in the SARS-CoV-2 receptor-binding domain coreSemantic proximity
Neutralizing Ability of a Single Domain VNAR Antibody: In Vitro Neutralization of SARS-CoV-2 Variants of ConcernSemantic proximity
Antibody Cocktail Exhibits Broad Neutralization against SARS-CoV-2 and SARS-CoV-2 variantsSemantic proximity
Deep mining of early antibody response in COVID-19 patients yields potent neutralisers and reveals high level of convergenceSemantic proximity
Prospective mapping of viral mutations that escape antibodies used to treat COVID-19.Semantic proximity
Rapid identification of a human antibody with high prophylactic and therapeutic efficacy in three animal models of SARS-CoV-2 infectionSemantic proximity
Identification of potent human neutralizing antibodies against SARS-CoV-2 implications for development of therapeutics and prophylacticsSemantic proximity
Select a neighboring publication to make it the new centre.